Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II
Saturday, November 7, 2020
9:00 AM – 11:00 AM ET
Poster session.
Presentations:
9:00 AM – 11:00 AM ET
Impact of Skin Involvement on Disease Burden Among Patients with Psoriatic Arthritis: Data from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry Philip J. Mease, MD – Seattle Rheumatology Associates
9:00 AM – 11:00 AM ET
A Multi-Center, Randomized, Double-blind, Placebo-controlled Dose-ranging Study Evaluating Efficacy and Safety of SHR-1314 in Subjects with Moderate-to-Severe Plaque Psoriasis Jinhua Xu – Huashan Hospital Affiliated to Fudan University
9:00 AM – 11:00 AM ET
Secukinumab Provides Sustained Improvements in Subgroup Analyses of Joint Tenderness and Swelling in Patients with Psoriatic Arthritis: 5‑Year Results from the Phase 3 FUTURE 2 Study Iain B. McInnes, FRCP – University of Glasgow
9:00 AM – 11:00 AM ET
Gender Differences in Baseline Clinical Characteristics Among Patients with Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis: Data from 3 Randomized Ixekizumab Controlled Trials Marina Magrey, MD – Case Western Reserve University School of Medicine at MetroHealth Medical Center
9:00 AM – 11:00 AM ET
Improvements in Global Functioning and Health-related Quality of Life and Their Association with Disease Activity and Functional Improvement in Patients with Active Ankylosing Spondylitis Treated with Upadacitinib Uta Kiltz, MD – Rheumazentrum Ruhrgebiet, Ruhr-University Bochum
9:00 AM – 11:00 AM ET
Absolute Lymphocyte Count Is Negatively Correlated with Atherosclerotic Cardiovascular Disease Risk Score and Red Cell Distribution Width in Psoriatic Arthritis and Increases with TNF-Inhibitor Therapy Angela Gupta, MD – Case Western Reserve University
9:00 AM – 11:00 AM ET
Application of Treat-to-Target in Axial Spondyloarthritis in Daily Practice Esther Beckers, MSc – Maastricht University Medical Center
9:00 AM – 11:00 AM ET
Ixekizumab Improves Signs and Symptoms of Patients with Radiographic and Non-radiographic Axial Spondyloarthritis and Extra-articular Manifestation of Enthesitis Through 16 Weeks Georg Schett, MD – Universitaetsklinikum Erlangen
9:00 AM – 11:00 AM ET
Reduction of Anterior Uveitis Flares in Patients with Axial Spondyloarthritis During Certolizumab Pegol Treatment: 96-Week Results from the C-VIEW Study Rianne E. van Bentum, MD – Amsterdam University Medical Center, location VUmc.
9:00 AM – 11:00 AM ET
Comparison of Disease Control Thresholds in Psoriatic Arthritis: Results from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry Philip J. Mease, MD – Seattle Rheumatology Associates
9:00 AM – 11:00 AM ET
Impact of HLA-B27 Status on Clinical Outcomes in Patients with Ankylosing Spondylitis Treated with Secukinumab Atul Deodhar, MD – Oregon Health & Science University
9:00 AM – 11:00 AM ET
Achievement of Partial Remission and Inactive Disease in Upadacitinib-Treated Patients with Ankylosing Spondylitis Atul Deodhar, MD – Oregon Health & Science University
9:00 AM – 11:00 AM ET
Increasing Use of Biologics in Treatment of Systemic Lupus Erythematosus Patients in US Clinical Practice: Real-World Observations from Trio Health and the American Rheumatology Network Simon Helfgott, MD – BWH- HMS
9:00 AM – 11:00 AM ET
Guselkumab Efficacy and Safety in TNF-Inhibitor-Experienced and TNF-Inhibitor-Naïve Patients with Active PsA: 1-Year Results of a Phase 3, Randomized, Controlled Study Christopher Ritchlin, MD, MPH – University of Rochester Medical Center
9:00 AM – 11:00 AM ET
Efficacy of Secukinumab Treatment in Patients with Early Psoriatic Arthritis: A Pooled Analysis of 4 Phase 3 Studies Christopher Ritchlin, MD, MPH – University of Rochester Medical Center
9:00 AM – 11:00 AM ET
Ixekizumab Treatment Improves Fatigue, Spinal Pain, Stiffness, and Sleep in Patients with Nonradiographic Axial Spondyloarthritis Philip J. Mease, MD – Seattle Rheumatology Associates
9:00 AM – 11:00 AM ET
Four-Year Efficacy and Safety of Guselkumab in Psoriasis Patients with and Without Psoriatic Arthritis: A Pooled Analysis from VOYAGE 1 and VOYAGE 2 Jan Dutz, MD – University of British Columbia
9:00 AM – 11:00 AM ET
Long-Term Safety Profile of Ixekizumab Treatment in Patients with Axial Spondyloarthritis Sergio Schwartzman, MD – Self Employed 72nd Street Medical Associates
9:00 AM – 11:00 AM ET
Is It Feasible to Achieve Recommended Therapeutic Target Objective in Patients with Axial Spondyloarthritis in Clinical Practice? Data from the SpA-paz Cohort KAREN N. FRANCO, MD – hospital universitario la paz
9:00 AM – 11:00 AM ET
Impact of Upadacitinib on Reducing Pain in Patients with Active Psoriatic Arthritis: Results from Two Phase 3 Trials in Patients with Inadequate Response to Non-biologic or Biologic DMARDs Iain B. McInnes, FRCP – University of Glasgow
9:00 AM – 11:00 AM ET
Temporal Achievement of Clinical Response and Inactive Disease Status in Patients with Axial Spondyloarthritis Treated with Etanercept Xenofon Baraliakos, MD – Rheumazentrum Ruhrgebiet Herne
9:00 AM – 11:00 AM ET
Inadequate Response Among Psoriatic Arthritis Patients Prescribed Advanced Therapy in a Real-world US Commercially Insured Population Michael Grabner, PhD – HealthCore, Inc.
9:00 AM – 11:00 AM ET
Secukinumab Provides Significant Improvement of Spinal Pain and Lowers Disease Activity in Patients with Axial Spondyloarthritis: 24-week Results from a Randomized Controlled Phase 3b Trial Denis Poddubnyy, MD, MSc – Charité - Universitätsmedizin Berlin
9:00 AM – 11:00 AM ET
Achievement of Low Disease Activity According to BASDAI with Ixekizumab in Patients with Axial Spondyloarthritis: 16-Week Results from the COAST Trials Denis Poddubnyy, MD, MSc – Charité - Universitätsmedizin Berlin
9:00 AM – 11:00 AM ET
Proinflammatory Neutrophil Function Is Modulated During Secukinumab Therapy in Psoriatic Arthritis Without Compromising Host Defence Robert Moots, MD, PhD – Edge Hill University
9:00 AM – 11:00 AM ET
Impact of Dose Escalation of Secukinumab in Patients with Psoriatic Arthritis in Real-World Setting María Martín López, PhD – Hospital Universitario 12 de octubre
9:00 AM – 11:00 AM ET
Changing Patterns of Use of Biologic/Targeted Synthetic DMARDs in Psoriatic Arthritis: An Analysis of the OPAL Dataset Sabina Ciciriello, MD – Melbourne Health
9:00 AM – 11:00 AM ET
Response to Ixekizumab by C-reactive Protein Level in Patients with Radiographic Axial Spondyloarthritis: Results from the COAST-V (Biological-Naïve) and COAST-W (TNF Inhibitor-Experienced) Trials at 52 Weeks John D. Reveille, MD – University of Texas McGovern Medical School
9:00 AM – 11:00 AM ET
Probability of Achieving Low Disease Activity or Remission with Apremilast Treatment Among DMARD-Naive Subjects with Active Psoriatic Arthritis Philip J. Mease, MD – Seattle Rheumatology Associates
9:00 AM – 11:00 AM ET
Bimekizumab Treatment Is Associated with Improvements in Back Pain and Fatigue in Patients with Active Psoriatic Arthritis: 48-Week Results from a Phase 2b Study Atul Deodhar, MD – Oregon Health & Science University
9:00 AM – 11:00 AM ET
Long-term Outcomes with Filgotinib, an Oral Selective Janus Kinase 1 Inhibitor: 100-week Data from an Open-label Extension (OLE) Study in Patients with Active Psoriatic Arthritis (PsA) Laura C. Coates, PhD, MBChB – University of Oxford
9:00 AM – 11:00 AM ET
Guselkumab Efficacy in Adult Patients with Active Psoriatic Arthritis by Baseline Demographic and Disease Characteristics: Pooled Results of Two Phase 3, Randomized, Placebo-Controlled Studies Atul Deodhar, MD – Oregon Health & Science University
9:00 AM – 11:00 AM ET
Residual Disease Activity in Psoriatic Arthritis Patients Treated with Secukinumab and Adalimumab Who Achieved Remission or Low Disease Activity: Results from a Phase 3b, Randomized, Double-blinded, Active-controlled, Head-to-head Study Iain B. McInnes, FRCP – University of Glasgow
9:00 AM – 11:00 AM ET
Effect of Filgotinib on the Complete Resolution of Enthesitis in Psoriatic Arthritis (PsA) Patients: 52-week Results from EQUATOR2 Philip J. Mease, MD – Seattle Rheumatology Associates
9:00 AM – 11:00 AM ET
Impact of Filgotinib on Structural Lesions in the Sacroiliac Joints at 12 Weeks in Patients with Active Ankylosing Spondylitis: Correlation with Clinical Endpoints Walter P. Maksymowych, MD, FRCPC – University of Alberta
9:00 AM – 11:00 AM ET
Efficacy and Safety of Secukinumab in Patients with Spondyloarthritis and Enthesitis at the Achilles Tendon: 52-weeks Results from a Randomized, Placebo-controlled Phase 3b Trial Frank Behrens, MD – Rheumatology & Fraunhofer TMP Goethe University Frankfurt, Germany
9:00 AM – 11:00 AM ET
Network Meta-Analysis of Long-Term Efficacy (ASAS40) of Biologic Disease-Modifying Anti-Rheumatic Drugs (bDMARDs) in bDMARD-Naïve Patients with Non-Radiographic Axial Spondyloarthritis Marissa Betts, MSc – Evidera
9:00 AM – 11:00 AM ET
Efficacy and Safety of Neihulizumab (AbGn-168H) in Patients with Active Psoriatic Arthritis: 24-week Results from a Phase II Open Label Study Stanley B. Cohen, MD – Metroplex Clinical Research Center
9:00 AM – 11:00 AM ET
Effects of Guselkumab, a Monoclonal Antibody That Specifically Binds to the p19-Subunit of Interleukin-23, on Dactylitis and Enthesitis in Patients with Active Psoriatic Arthritis: Pooled Results Through Week 24 from Two Phase 3 Studies Dennis McGonagle, PhD, MB, FRCPI – University of Leeds
